s
s
s
Develop an ADA assay for Fab fragment drug certolizumab pegol (Cimzia) using ready-made anti-idiotypic antibodies.
Table 1. Antibodies Specific to Certolizumab Pegol.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Certolizumab pegol Type 1 |
HCA324 |
AbD34136ia |
Human IgG1 |
3.0 |
ADA control |
|
HCA325 |
AbD34201ia |
Human IgG1 |
1.0 |
ADA control |
||
HCA326 |
AbD34202ia |
Human IgG1 |
2.0 |
ADA control |
* Affinity measured in the monovalent Fab format
Type 1 anti-certolizumab pegol antibodies inhibit the binding of the drug certolizumab pegol to its target, tumor necrosis factor alpha (TNFα). They are available with three different affinities, and are suitable as a surrogate positive control or reference standard for an anti-drug antibody (ADA) assay.
Fig. 1. Certolizumab pegol ADA bridging ELISA using antibody HCA324, HCA325 or HCA326.
Schematic image of ADA bridging assay. Monovalent Fab fragment drug as capture and detection reagent labeled with HRP (gold), fully human anti-drug antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.